Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Century Therapeutics (IPSC) Revenue (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Revenue for 4 consecutive years, with $109.2 million as the latest value for Q1 2025.

  • Quarterly Revenue rose 12667.72% to $109.2 million in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $109.2 million through Dec 2025, up 1556.51% year-over-year, with the annual reading at $109.2 million for FY2025, 1556.76% up from the prior year.
  • Revenue for Q1 2025 was $109.2 million at Century Therapeutics, up from $4.2 million in the prior quarter.
  • The five-year high for Revenue was $109.2 million in Q1 2025, with the low at $99000.0 in Q2 2023.
  • Average Revenue over 4 years is $9.5 million, with a median of $855000.0 recorded in 2024.
  • The sharpest move saw Revenue tumbled 93.35% in 2023, then skyrocketed 12667.72% in 2025.
  • Over 4 years, Revenue stood at $521000.0 in 2022, then plummeted by 48.56% to $268000.0 in 2023, then soared by 1457.09% to $4.2 million in 2024, then skyrocketed by 2515.96% to $109.2 million in 2025.
  • According to Business Quant data, Revenue over the past three periods came in at $109.2 million, $4.2 million, and $791000.0 for Q1 2025, Q4 2024, and Q3 2024 respectively.